CellSource Co., Ltd.
Stock Price Chart
2026/09/11 UpdatedPrice Trend
2026/09/11 UpdatedPrice & Trading Details
2026/09/11 UpdatedPRICE
TRADING
Shareholder Composition
Updated 2026/09/01Dividend History
Updated 2026/09/13| Year | Dividend | Change |
|---|---|---|
| 2025 | ¥5 | 0.0% |
| 2024 | ¥5 | -75.0% |
| 2023 | ¥20 | - |
Financial Performance
2026/09/13 UpdatedRevenue & Profit
Margins
Cash Flow
Financial Health
| 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|
| Income Statement | ||||
| Revenue | ¥4,274M | ¥4,511M | ¥4,355M | ¥3,711M |
| Gross Profit | ¥3,064M | ¥3,185M | ¥2,417M | ¥2,087M |
| Operating Income | ¥1,571M | ¥1,222M | ¥129M | ¥167M |
| Pretax Income | ¥1,584M | ¥1,240M | ¥296M | ¥111M |
| Net Income | ¥1,018M | ¥923M | ¥238M | ¥11M |
| EPS | ¥52.98 | ¥47.93 | ¥11.96 | ¥0.54 |
| Operating Margin | 36.76% | 27.08% | 2.97% | 4.49% |
| Balance Sheet | ||||
| Total Assets | ¥4,600M | ¥6,880M | ¥7,075M | ¥7,024M |
| Total Equity | ¥3,786M | ¥6,202M | ¥6,037M | ¥6,017M |
| Total Liabilities | ¥814M | ¥678M | ¥1,038M | ¥1,007M |
| Cash | ¥3,124M | ¥4,781M | ¥4,321M | ¥4,712M |
| Interest-bearing Debt | ¥0M | ¥98M | ¥77M | ¥57M |
| Equity Ratio | 82.30% | 90.15% | 85.33% | 85.66% |
| D/E Ratio | 0.00 | 0.02 | 0.01 | 0.01 |
| Cash Flow | ||||
| Operating CF | ¥848M | ¥847M | ¥592M | ¥333M |
| Investing CF | -¥169M | -¥624M | -¥615M | -¥3M |
| Financing CF | ¥14M | ¥1,449M | -¥437M | ¥61M |
| Free CF | ¥748M | ¥488M | ¥52M | ¥283M |
| Efficiency | ||||
| ROE | 26.89% | 14.88% | 3.94% | 0.18% |
| ROA | 22.13% | 13.42% | 3.36% | 0.15% |
Latest IR Information
-
Notice on Changes in Major Shareholders andセルソース株式取得
Announces plan to acquire 5,000,000 shares ofセルソース株式 (25.24% of total voting rights). Also notes a shareholder change to Serial Incubator Co., Ltd., with Masayuki Yamakawa, the representative director, serving as head of a long-term-owned asset management company. Change date: 2026-09-09.
Read more -
Notice of Recording of Income Tax Adjustment (Loss)
For the cumulative third quarter of the fiscal year ending October 2026, an income tax adjustment (loss) of 38 million yen is recorded. As a result, quarterly net income increases. A write-down of deferred tax assets occurred due to a...
Read more -
Monthly KPI Quick Report for October 2026
The average number of processing contracts in August is slightly below the same month last year at 49.1 cases. Blood-derived processing contracts decline for self-pay specialty orthopedic clinics, while hybrid clinics increase. By department, self-pay specialty clinics show 639 cases,...
Read more -
Notice Regarding Revision of Earnings Guidance
Revised the full-year forecast for the fiscal year ending October 2026. Net sales to 3,367 million yen from 3,320 million yen; operating income to 82 million yen from -221 million yen; ordinary income to 76 million yen from -210 million...
Read more -
Fiscal Year Ending October 2026 Q3 Financial Results Summary [Japanese GAAP] (Non-Consolidated)
For the third quarter of the fiscal year ending October 2026, net sales were 2,567,467 thousand yen, operating income was 179,232 thousand yen, and quarterly net income was 174,484 thousand yen. Following the absorption of Hybrid Medical Co., Ltd., disclosures...
Read more
Latest News (5 items)
Company Information
About
CellSource Co., Ltd. engages in the regenerative medicine-related businesses in Japan. The company provides processing services to extract adipose-derived stem cells from patients' adipose tissues, and to prepare platelet-rich plasma from patients' blood; and offers support services for medical facilities providing regenerative medicine therapy. It is also involved in the sale of human stem cell-derived cosmetic ingredients; and Signalift series of anti-aging products, including a serum. The company was incorporated in 2015 and is headquartered in Shibuya, Japan.
